Luigi Taranto Montemurro, MD

Chief Scientific Officer

Luigi Taranto is one of the scientific founders of Apnimed. His original work at the Brigham and Women’s Hospital provided the proof of concept for the first combination of drugs for the treatment of obstructive sleep apnea under development at Apnimed. Before joining Apnimed in early 2020, he was responsible for the sleep apnea drug discovery program in Andrew Wellman’s laboratory at Harvard. Previously, he held postdoctoral fellowships at Harvard Medical School. He has an extensive clinical background in sleep medicine, receiving an MD from the University of Brescia, Italy, and then completing clinical training in respiratory and sleep medicine in Italy and the University of Toronto. He has coauthored more than 50 articles and book chapters in this area.